STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANRO
  4. [Form 4] Alto Neuroscience, Inc. Insider Trading Activity

Alto Neuroscience (ANRO) director awarded 3,806 stock options in lieu of fees

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Alto Neuroscience, Inc. reported that one of its directors received a grant of stock options. On 01/02/2026, the director was granted 3,806 stock options to purchase Alto Neuroscience common stock. These options were issued under the company’s Non-Employee Director Compensation Policy in lieu of $45,000 in retainer fees.

The options vest in four quarterly installments during 2026, subject to the director’s continued service. 952 options vest on March 31, 2026, 951 options on June 30, 2026, 952 options on September 30, 2026, and 951 options on December 31, 2026. Any unvested portion would not be earned if service ends before the relevant vesting date.

Positive

  • None.

Negative

  • None.
Insider Sanchez Ramiro
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,806 $11.82 $45K
Holdings After Transaction: Stock Option (right to buy) — 3,806 shares (Direct)
Footnotes (1)
  1. 952 shares underlying the option shall vest on March 31, 2026, 951 shares underlying the option shall vest on June 30, 2026, 952 shares underlying the option shall vest on September 30, 2026 and 951 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $45,000.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sanchez Ramiro
(Last) (First) (Middle)
C/O ALTO NEUROSCIENCE, INC.
650 CASTRO STREET, SUITE 450
(Street)
MOUNTAIN VIEW CA 94041
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Alto Neuroscience, Inc. [ ANRO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $16.59 01/02/2026 A 3,806 (1) 01/01/2036 Common Stock 3,806 $11.82(2) 3,806 D
Explanation of Responses:
1. 952 shares underlying the option shall vest on March 31, 2026, 951 shares underlying the option shall vest on June 30, 2026, 952 shares underlying the option shall vest on September 30, 2026 and 951 shares underlying the option shall vest on December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.
2. This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $45,000.
Remarks:
/s/ Erin R. McQuade, Attorney-in-Fact 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Alto Neuroscience (ANRO) disclose in this Form 4 filing?

The filing reports that a director of Alto Neuroscience received a grant of 3,806 stock options to buy the company’s common stock as part of director compensation.

How many Alto Neuroscience stock options were granted to the director?

The director was granted 3,806 stock options to purchase Alto Neuroscience common stock.

What is the vesting schedule for the 3,806 Alto Neuroscience stock options?

The options vest in four installments during 2026: 952 options on March 31, 951 options on June 30, 952 options on September 30, and 951 options on December 31, subject to continued service.

Why were these Alto Neuroscience (ANRO) stock options issued to the director?

The options were issued under Alto Neuroscience’s Non-Employee Director Compensation Policy in lieu of $45,000 in retainer fees.

What role does the reporting person have at Alto Neuroscience?

The reporting person is a director of Alto Neuroscience, as indicated by the relationship section of the filing.

What happens if the Alto Neuroscience director stops serving before all options vest?

The filing states that each vesting tranche is subject to the director’s continuous service through the applicable vesting date, so unvested options would not be earned if service ends earlier.